Home
Corporate
Operations
- R & D
- Project Portfolio
- Prioritized projects
  - Lipsovir
  - TMC435
  - MIV-701
  - HIV PI
  - HCV POL
  - KOL PI
  - Renin
  - BACE
  - Cathepsin K
  - Cathepsin S
- Polymerase inhibitor projects
  - Valomaciclovir
  - Alovudine
  - MIV-210
  - MIV-150
  - MIV-410
  - MIV-160
- Technologies
- Patents
IR & Media
Career and Contact
Search

MIV-410

Therapy Area
NRTI for the treatment of patients with multiresistant HIV and of cytomegaloviral infection in immuno-deficient patients.

Competitive Edge
Potent NRTI with new inhibition
mechanism.

Licensee
Presidio Pharmaceuticals

Last Modified: 05/09/2008